# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Charlotte Brontë (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI025-SYN
- Date: 2026-01-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Thwaite, MD
- Calendar frame: modern shifted

## What we are working on

- Nausea most of the day for a week and vomiting three or four times a day; she can no longer face meals and has lost about a kilogram **S**
- She is glad of the pregnancy but anxious about her age and about her own health, having lost her mother and her sisters young **S**
- She asks whether she could carry tuberculosis, since it was in her household **S**

## Your goals

- Nausea and vomiting mild (PUQE-24 score 6 or less) and weight back to her pre-pregnancy 46.0 kg by about 17 weeks. Target: 2026-03-24. Recorded outcome: PUQE-24 score 4 and weight 46.2 kg at 17 weeks 1 day. **S**
- Hydration and electrolytes normal within two weeks of any admission. Target: 2026-02-10. Recorded outcome: Sodium, potassium, chloride, bicarbonate, magnesium, phosphate, and transaminases all normal nine days after discharge. **S**
- An informed choice about aneuploidy screening and diagnostic testing by 13 weeks. Target: 2026-02-24. Recorded outcome: Chose cell-free DNA screening (low risk) and the nuchal translucency scan (1.5 mm); declined diagnostic testing. **S**
- Low-dose aspirin started between 12 and 16 weeks if indicated. Target: 2026-02-24. Recorded outcome: Started at 13 weeks 1 day for two moderate risk factors. **S**
- Tuberculosis screening completed and explained by the second visit. Target: 2026-01-20. Recorded outcome: Interferon-gamma release assay negative; no latent infection; no chest radiograph needed. **S**
- Mood screened in each trimester, with support offered. Target: 2026-03-24. Recorded outcome: PHQ-9 5 at intake, EPDS 9 after the admission and 5 at 17 weeks; item 10 scored 0 each time. **S**

## What we agreed to do

- First prenatal visit: dating ultrasound; blood count, blood group and antibody screen, rubella immunity, hepatitis B surface antigen, HIV, syphilis, and hepatitis C tests; urine culture; metabolic panel and urinalysis because of vomiting; influenza vaccine; folic acid 0.4 mg daily in place of the iron-containing prenatal vitamin while nausea lasts. Guideline: USPSTF A and B Recommendations (2026); Guidelines for Vaccinating Pregnant Persons (2026) **S**
- Nausea and vomiting, step by step: small frequent dry meals, fluids between meals, ginger if she wishes, and avoiding smells that trigger nausea; doxylamine-pyridoxine from today, raised to four tablets a day if needed; then a second drug (metoclopramide, promethazine, or ondansetron after counseling); PUQE-24 score, weight, pulse, blood pressure, and electrolytes at each visit; same-day review if she cannot keep fluids down for 24 hours or loses more than 5 percent of her pre-pregnancy weight. Guideline: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024) **S**
- Maternal-fetal medicine consultation for a first pregnancy at 38 with moderate nausea and vomiting and early weight loss: escalation thresholds, aneuploidy screening and diagnostic options, preeclampsia prevention, tuberculosis risk, and the plan for the rest of the pregnancy. Guideline: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024); Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021) **S**
- Aneuploidy screening offered to all, with diagnostic testing available: cell-free DNA from 10 weeks, a nuchal translucency scan at 11 to 14 weeks, or chorionic villus sampling or amniocentesis; a detailed anatomy scan at 18 to 22 weeks. Guideline: Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020) **S**
- Tuberculosis screening with an interferon-gamma release assay because of tuberculosis deaths in her household; a shielded chest radiograph and treatment decisions only if it is positive. Guideline: Latent Tuberculosis Infection in Adults: Screening (2023) **S**
- Mental health: PHQ-9 at intake and the EPDS in each trimester and after any admission, with support for the strain of severe vomiting and for anxiety rooted in family loss. Guideline: Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum (Clinical Practice Guideline No. 4) (2023); Perinatal Depression: Preventive Interventions (2019) **S**
- Preeclampsia prevention: low-dose aspirin 81 mg at bedtime from 12 to 16 weeks until delivery if she has one high-risk or more than one moderate-risk factor (she has two: first pregnancy and age 35 or older); blood pressure at every visit. Guideline: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021) **S**
- Admission for hyperemesis gravidarum: 0.9% saline with potassium chloride guided by daily electrolytes; thiamine 100 mg intravenously before any dextrose, then orally; magnesium replacement; ondansetron after counseling and an electrocardiogram; stop metoclopramide; refeeding precautions with phosphate and magnesium checks as eating resumes; weight-adjusted enoxaparin while admitted; discharge when she keeps fluids and food down. Guideline: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024); Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium (Green-top Guideline No. 37a) (2015) **S**
- Thyroid: suppressed TSH with a mildly raised free T4 during hyperemesis is gestational transient thyrotoxicosis; no antithyroid drug; repeat TSH and free T4 at 16 to 18 weeks, and test for TSH-receptor antibodies only if it persists or signs of Graves disease appear. Guideline: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum (2017) **S**
- Monitoring while nausea and vomiting last: PUQE-24, weight, pulse, and blood pressure at every visit; electrolytes until stable on oral intake; liver tests if abnormal; mood each trimester; antiemetic side effects (drowsiness, restlessness or abnormal movements, constipation, palpitations). Guideline: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024) **S**

## Follow-up

- 2026-01-13: First prenatal visit at 7 weeks with nausea and vomiting for a week and early weight loss: dating ultrasound, prenatal tests, and a plan for the nausea **S**
- 2026-01-20: One-week review of nausea and vomiting, intake results, and maternal-fetal medicine consultation **S**
- 2026-02-10: Prenatal visit at 11 weeks: nausea and vomiting review and cell-free DNA screening **S**
- 2026-02-24: Prenatal visit at 13 weeks with the nuchal translucency scan and the low-dose aspirin decision **S**
- 2026-03-24: Prenatal visit at 17 weeks: nausea and vomiting review and thyroid recheck **S**

This teaching document does not replace care from a qualified clinician.
